HOME Top Market Reports Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019

Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019

By: marketsandmarkets.com
Publishing Date: March 2015
Report Code: MD 3687

Discount on Reports  

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The blood screening market is expected to reach $2.54 billion by 2019 from $1.55 billion in 2014, at a CAGR of 10.4%. High growth in this market can be attributed to the increasing number of blood donations and blood donors, rising awareness regarding safety of donated blood, increasing affordability to pay for NAT-tested blood, increasing adoption rate for NAT testing, growing demand for donated blood, and increasing prevalence/incidence of infectious diseases.

North America dominated the blood screening market, with the U.S. accounting for a major market share. However, Asia is poised to grow at the highest CAGR during the forecast period. Increasing prevalence and incidence of infectious diseases, high demand for donated blood, and increased awareness among people regarding the safety of donated blood are driving the blood screening market in this region.

Prominent players in this market are Grifols (Spain), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), bioMιrieux (France), Bio-Rad Laboratories, Inc. (U.S.), Siemens Healthcare (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.) and Beckman Coulter (U.S.).

Scope of the Report

This research report covers this market by technology, products and services, end users, and regions.

Blood Screening Market, by Technology

  • Nucleic Acid Test (NAT)
    • Transcription Mediated Amplification (TMA)
    • Real-time Polymerase Chain Reaction (PCR)
  • ELISA
    • Rapid Test (Card Methodology)
    • First-generation ELISA
    • Second-generation ELISA
    • Third-generation ELISA
    • Fourth-generation ELISA
  • Enzyme Immunoassays (EIAs) and Chemiluminescent Immunoassays (CLIAs)
  • Next-generation Sequencing (NGS)
  • Western Blot Assays

Blood Screening Market, by Products and Services

  • Instruments (Hardware)
    • Purchase Modes
      • Rental Purchase
      • Outright Purchase
    • Reagents
      • ELISA Reagents
        • Immunosorbents
        • Conjugates
        • Substrates
        • Controls
        • Sample Diluent and Wash Solutions
      • NAT Reagents
        • Enzymes and Polymerases
        • Probes and Primers
        • Buffers, Nucleotides, and Solutions
        • Labeling and Detection Reagents
        • Standards and Controls
      • Other Reagents
    • Software and Services

Blood Screening Market, by End User

  • Blood Banks
  • Hospitals

Blood Screening Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  •   Asia
    • China
    • India
    • Japan
  • Rest of the World (ROW)

Table of Contents

1 Introduction (Page No. - 18)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Stakeholders

2 Research Methodology (Page No. - 21)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
    2.3 Market Share Estimation
    2.4 Key Data From Secondary Sources
    2.5 Key Data From Primary Sources
    2.6 Key Industry Insights
    2.7 Assumptions for the Study

3 Executive Summary (Page No. - 28)

4 Premium Insights (Page No. - 33)
    4.1 Blood Screening Market, By Technology
    4.2  By Products and Services
    4.3 Blood Screening Reagents Market
    4.4 Blood Screening ELISA Market
    4.5 Blood Screening Market, By End User
    4.6 Geographic Snapshot

5 Market Overview (Page No. - 34)
    5.1 Introduction
    5.2 Market Segmentation
           5.2.1 Blood Screening Market Segmentation, By Technology
           5.2.2  Market Segmentation, By Products and Services
           5.2.3  Market Segmentation, By End User
           5.2.4 Market Segmentation, By Region
    5.3 Market Dynamics
           5.3.1 Drivers
                    5.3.1.1 Increasing Number of Blood Donations and Blood Donors
                    5.3.1.2 Rising Awareness Regarding Safety of Donated Blood
                    5.3.1.3 Increase in Patient Affordability to Pay for NAT Tested Blood
                    5.3.1.4 Growing Adoption of NAT  for Blood Screening
                    5.3.1.5 Increasing Demand of Donated Blood
                    5.3.1.6 Rising Prevalence of Infectious Diseases
           5.3.2 Restraints
                    5.3.2.1 Capital Expenditure and Operating Cost of NAT Testing
                    5.3.2.2 Lack of Mandate for NAT in Developing Countries
                    5.3.2.3 Digital Immunoassay is New Alternative Technology
           5.3.3 Opportunities
                    5.3.3.1 Pathogen Reduction Technology
                    5.3.3.2 Microbiology Screening
                    5.3.3.3 Multiplexing (Single Test for HIV, HBV, & HCV)
           5.3.4 Challenges
                    5.3.4.1 Price Reduction
                    5.3.4.2 Lack of Trained Manpower
                    5.3.4.3 Regulatory Challenges

6 Industry Trends (Page No. - 48)
    6.1 Supply Chain Analysis
    6.2 Pest Analysis
           6.2.1 Political Factors
           6.2.2 Economic Factors
           6.2.3 Social Factors
           6.2.4 Technical Factors
    6.3 Porter’s Five Force Analysis
           6.3.1 Threat From New Entrants
           6.3.2 Threat From Substitute Technologies
           6.3.3 Bargaining Power of Suppliers
           6.3.4 Bargaining Power of Buyers
           6.3.5 Intensity of Competitive Rivalry

7 Blood Screening Market, By Technology (Page No. - 54)
    7.1 Introduction
    7.2 Blood Screening Market, By Volume (Number of Tests Conducted)
           7.2.1 Transcription-Mediated Amplification
           7.2.2 Real-Time Polymerase Chain Reaction (PCR)
    7.3 Enzyme-Linked Immunosarbent Assay (ELISA)
           7.3.1 Rapid Test (Card Methodology)
           7.3.2 1st Generation ELISA
           7.3.3 2nd Generation ELISA
           7.3.4 3rd Generation ELISA
           7.3.5 4th Generation ELISA
    7.5 Next-Generation Sequencing (NGS)
    7.6 Western Blot Assay

8 Blood Screening Market, By Products and Services (Page No. - 84)
    8.1 Introduction
    8.2 Instruments (Hardware)
           8.2.1 Rental Purchase
           8.2.2 Outright Purchase
    8.3 Reagents
           8.3.1 ELISA Reagents
                    8.3.1.1 Immunosorbent
                    8.3.1.2 Controls
                    8.3.1.3 Conjugate (Antigen Or Antibody Conjugated Enzyme)
                    8.3.1.4 Substrate (Substrate of Enzyme)
                    8.3.1.5 Sample Diluents and Wash Solutions
           8.3.2 NAT Reagents
                    8.3.2.1 Enzymes and Polymerases
                    8.3.2.2 Standards and Controls
                    8.3.2.3 Probes & Primers
                    8.3.2.4 Buffers, Nucleotides, and Solutions
                    8.3.2.5 Labeling & Detection Reagents
           8.3.3 Other Reagents
    8.4 Software and Services

9 Blood Screening Market, By End User (Page No. - 105)
    9.1 Introduction
    9.2 Blood Banks
    9.3 Hospitals

10 Blood Screening Market, By Region (Page No. - 112)
     10.1 Introduction
             10.1.1 North America
             10.1.2 U.S.
             10.1.3 Canada
     10.2 Europe
             10.2.1 Germany
             10.2.2 France
             10.2.3 U.K.
             10.2.4 Italy
             10.2.5 Spain
             10.2.6 Rest of Europe (ROE)
     10.3 Asia
             10.3.1 Japan
             10.3.2 China
             10.3.3 India
             10.3.4 Rest of Asia (ROA)
     10.4 Rest of the World (ROW)

11 Competitive Landscape (Page No. - 158)
     11.1 Overview
     11.2 Market Share Analysis
             11.2.1 Market Share Analysis for NAT
             11.2.2 Market Share Analysis for Blood Screening
     11.3 Competitive Situations and Trends
             11.3.1 New Product Launches
             11.3.2 Mergers and Acquisitions
             11.3.3 Regulatory Approvals
             11.3.4 Partnerships and Agreements

12 Company Profiles (Page No. - 166)
     12.1 Introduction
     12.2 Grifols
             12.2.1 Business Overview
             12.2.2 Product Portfolio
             12.2.3 Key Strategy
             12.2.4 Recent Developments
             12.2.5 MNM View
     12.3 Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd)
             12.3.1 Business Overview
             12.3.2 Product Portfolio
             12.3.3 Key Strategy
             12.3.4 Recent Developments
             12.3.5 MNM View
     12.4 Abbott Laboratories
             12.4.1 Business Overview
             12.4.2 Product Portfolio
             12.4.3 Key Strategy
             12.4.4 Recent Developments
             12.4.5 MNM View
     12.5 Biomιrieux
             12.5.1 Business Overview
             12.5.2 Product Portfolio
             12.5.3 Key Strategy
             12.5.4 Recent Developments
             12.5.5 MNM View
     12.6 Bio-Rad Laboratories, Inc.
             12.6.1 Business Overview
             12.6.2 Product Portfolio
             12.6.3 Key Strategy
             12.6.4 Recent Developments
             12.6.5 MNM View
     12.7 Siemens Healthcare (Subsidiary of Siemens AG)
             12.7.1 Business Overview
             12.7.2 Product Portfolio
             12.7.3 Key Strategy
             12.7.4 Recent Developments
     12.8 Ortho-Clinical Diagnostics, Inc.
             12.8.1 Business Overview
             12.8.2 Product Portfolio
             12.8.3 Key Strategy
             12.8.4 Recent Developments
     12.9 Thermo Fisher Scientific, Inc.
             12.9.1 Business Overview
             12.9.2 Product Portfolio
             12.9.3 Key Strategy
             12.9.4 Recent Development
     12.1 Beckman Coulter (Subsidiary of Danaher Corporation)
             12.10.1 Business Overview
             12.10.2 Product Portfolio
             12.10.3 Key Strategy
             12.10.4 Recent Developments
     12.11 Becton, Dickinson and Company
             12.11.1 Business Overview
             12.11.2 Product Portfolio
             12.11.3 Key Strategy
             12.11.4 Recent Developments

13 Appendix (Page No. - 194)


List of Tables (197 Tables)

Table 1 Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 2 Global Market, By Volume (Number of Tests), 2014
Table 3 North America: Blood Screening Market, By Volume (Number of Tests), 2014
Table 4 Europe: Market, By Volume (Number of Tests),2014
Table 5 Asia: Market, By Volume (Number of Tests), 2014
Table 6 Blood Screening NAT Technology Market Size, By Region, 2012–2019 ($Million)
Table 7 North America: Blood Screening NAT Technology Market Size, By Country, 2012–2019 ($Million)
Table 8 Europe: Blood Screening NAT Technology Market Size, By Country/Region, 2012–2019 ($Million)
Table 9 Asia: Blood Screening NAT Technology Market Size, By Country/Region, 2012–2019 ($Million)
Table 10 North America: Blood Screening NAT Technology Market Size, By Type, 2012–2019 ($Million)
Table 11 Transcription-Mediated Amplification Technology Market Size, By Region, 2012–2019 ($Million)
Table 12 North America: Transcription-Mediated Amplification Technology Market Size, By Country, 2012–2019 ($Million)
Table 13 Europe: Transcription-Mediated Amplification Technology Market Size, By Country/Region, 2012–2019 ($Million)
Table 14 Asia: Transcription-Mediated Amplification Technology Market Size, By Country/Region, 2012–2019 ($Million)
Table 15 Real-Time PCR Technology Market Size, By Region, 2012–2019 ($Million)
Table 16 North America: Real-Time PCR Technology Market Size, By Country, 2012–2019 ($Million)
Table 17 Europe: Real-Time PCR Technology Market Size, By Country/Region, 2012–2019 ($Million)
Table 18 Asia Real-Time PCR Technology Market Size, By Country/Region, 2012–2019 ($Million)
Table 19 ELISA Market Size, By Region, 2012–2019 ($Million)
Table 20 North America: ELISA Market Size, By Country, 2012–2019 ($Million)
Table 21 Europe: ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 22 Asia: ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 23 ELISA Market Size, By Type, 2012–2019 ($Million)
Table 24 Rapid Test (Card Methodology) Market Size, By Region, 2012–2019 ($Million)
Table 25 North America: Rapid Test (Card Methodology) Market Size, By Country, 2012–2019 ($Million)
Table 26 Europe: Rapid Test (Card Methodology) Market Size, By Country/Region, 2012–2019 ($Million)
Table 27 Asia: Rapid Test (Card Methodology) Market Size, By Country/Region, 2012–2019 ($Million)
Table 28 1st Generation ELISA Market Size, By Region, 2012–2019 ($Million)
Table 29 North America: 1st Generation ELISA Market Size, By Country, 2012–2019 ($Million)
Table 30 Europe: 1st Generation ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 31 Asia: 1st Generation ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 32 2nd Generation ELISA Market Size, By Region, 2012–2019 ($Million)
Table 33 North America: 2nd Generation ELISA Market Size, By Region, 2012–2019 ($Million)
Table 34 Europe: 2nd Generation ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 35 Asia: 2nd Generation ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 36 3rd Generation ELISA Market Size, By Region, 2012–2019 ($Million)
Table 37 North America: 3rd Generation ELISA Market Size, By Country, 2012–2019 ($Million)
Table 38 Europe: 3rd Generation ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 39 Asia: 3rd Generation ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 40 4th Generation ELISA Market Size, By Region, 2012–2019 ($Million)
Table 41 North America: 4th Generation ELISA Market Size, By Country, 2012–2019 ($Million)
Table 42 Europe: 4th Generation ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 43 Asia: 4th Generation ELISA Market Size, By Country/Region, 2012–2019 ($Million)
Table 44 EIAS and CLIAS Market Size, By Region, 2012–2019 ($Million)
Table 45 North America: EIAS and CLIAS Market Size, By Region, 2012–2019 ($Million)
Table 46 Europe: EIAS and CLIAS Market Size, By Country/Region, 2012–2019 ($Million)
Table 47 Asia: EIAS and CLIAS Market Size, By Country/Region, 2012–2019 ($Million)
Table 48 NGS Market Size, By Region, 2012–2019 ($Million)
Table 49 North America: NGS Market Size, By Region, 2012–2019 ($Million)
Table 50 Europe: NGS Market Size, By Country/Region, 2012–2019 ($Million)
Table 51 Asia: NGS Market Size, By Country/Region, 2012–2019 ($Million)
Table 52 Western Blot Assay Market Size, By Region, 2012–2019 ($Million)
Table 53 North America: Western Blot Assay Market Size, By Country, 2012–2019 ($Million)
Table 54 Europe: Western Blot Assay Market Size, By Country/Region, 2012–2019 ($Million)
Table 55 Asia: Western Blot Assay Market Size, By Country/Region, 2012–2019 ($Million)
Table 56 Blood Screening Market Size, By Products and Services, 2012–2019 ($Million)
Table 57 Blood Screening Instruments Market Size, By Region, 2012–2019 ($Million)
Table 58 North America: Blood Screening Instruments Market Size, By Country, 2012–2019 ($Million)
Table 59 Europe: Instruments Market Size, By Country, 2012–2019 ($Million)
Table 60 Asia: Instruments Market Size, By Country, 2012–2019 ($Million)
Table 61 Instruments Market Size, By Mode of Purchase, 2012–2019 ($Million)
Table 62 Reagents Market Size, By Region, 2012–2019 ($Million)
Table 63 North America: Blood Screening Reagents Market Size, By Country, 2012–2019 ($Million)
Table 64 Europe: Blood Screening Reagents Market Size, By Country, 2012–2019 ($Million)
Table 65 Asia: Reagents Market Size, By Country, 2012–2019 ($Million)
Table 66 Reagents Market Size, By Type, 2012–2019 ($Million)
Table 67 Blood Screening ELISA Reagents Market Size, By Region, 2012–2019 ($Million)
Table 68 North America: ELISA Reagents Market Size, By Country, 2012–2019 ($Million)
Table 69 Europe: ELISA Reagents Market Size, By Country, 2012–2019 ($Million)
Table 70 Asia: ELISA Reagents Market Size, By Country, 2012–2019 ($Million)
Table 71 ELISA Reagents Market Size, By Type, 2012–2019 ($Million)
Table 72 Blood Screening NAT Reagents Market Size, By Region, 2012–2019 ($Million)
Table 73 North America: NAT Reagents Market Size, By Country, 2012–2019 ($Million)
Table 74 Europe: NAT Reagents Market Size, By Country, 2012–2019 ($Million)
Table 75 Asia: NAT Reagents Market Size, By Country, 2012–2019 ($Million)
Table 76 NAT Reagents Market Size, By Type, 2012–2019 ($Million)
Table 77 Blood Screening Other Reagents Market Size, By Region, 2012–2019 ($Million)
Table 78 North America: Other Reagents Market Size, By Country, 2012–2019 ($Million)
Table 79 Europe: Other Reagents Market Size, By Country, 2012–2019 ($Million)
Table 80 Asia: Other Reagents Market Size, By Country, 2012–2019 ($Million)
Table 81 Software and Services Market Size, By Region, 2012–2019 ($Million)
Table 82 North America: Blood Screening Software and Services Market Size, By Country, 2012–2019 ($Million)
Table 83 Europe: Software and Services Market Size, By Region, 2012–2019 ($Million)
Table 84 Asia: Software and Services Market Size, By Country, 2012–2019 ($Million)
Table 85 Blood Screening Market Size, By End User, 2012–2019 ($Million)
Table 86 Market Size for Blood Banks, By Region, 2012–2019 ($Million)
Table 87 North America: Market Size for Blood Banks, By Country, 2012–2019 ($Million)
Table 88 Europe: Market Size for Blood Banks, By Country, 2012–2019 ($Million)
Table 89 Asia: Market Size for Blood Banks, By Country, 2012–2019 ($Million)
Table 90 Blood Screening Market Size for Hospitals, By Region, 2012–2019 ($Million)
Table 91 North America: Blood Screening Market Size for Hospitals, By Country, 2012–2019 ($Million)
Table 92 Europe: Market Size for Hospitals, By Country, 2012–2019 ($Million)
Table 93 Asia: Market Size for Hospitals, By Country, 2012–2019 ($Million)
Table 94 Global Blood Screening Market Size, By Region, 2012–2019 ($Million)
Table 95 North America: Blood Screening Market Size, By Country, 2012–2019 ($Million)
Table 96 Europe: Market Size, By Country, 2012–2019 ($Million)
Table 97 Asia: Market Size, By Country, 2012–2019 ($Million)
Table 98 North America: Market Size, By Technology, 2012–2019 ($Million)
Table 99 North America: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 100 North America: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 101 North America: Market Size, By Products and Services, 2012–2019 ($Million)
Table 102 North America: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 103 North America: Market Size, By End User, 2012–2019 ($Million)
Table 104 U.S.: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 105 U.S.: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 106 U.S.: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 107 U.S.: Market Size, By Products & Services, 2012–2019 ($Million)
Table 108 U.S.: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 109 U.S.: Market Size, By End User, 2012–2019 ($Million)
Table 110 Canada: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 111 Canada: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 112 Canada: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 113 Canada: Market Size, By Products & Services, 2012–2019 ($Million)
Table 114 Canada: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 115 Canada: Market Size, By End User, 2012–2019 ($Million)
Table 116 Europe: Market Size, By Technology, 2012–2019 ($Million)
Table 117 Europe: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 118 Europe: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 119 Europe: Market Size, By Products and Services, 2012–2019 ($Million)
Table 120 Europe: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 121 Europe: Market Size, By End User, 2012–2019 ($Million)
Table 122 Germany: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 123 Germany: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 124 Germany: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 125 Germany: Market Size, By Products & Services, 2012–2019 ($Million)
Table 126 Germany: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 127 Germany: Market Size, By End User, 2012–2019 ($Million)
Table 128 France: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 129 France: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 130 France: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 131 France: Market Size, By Products & Services, 2012–2019 ($Million)
Table 132 France: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 133 France: Market Size, By End User, 2012–2019 ($Million)
Table 134 U.K.: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 135 U.K.: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 136 U.K.: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 137 U.K.: Market Size, By Products & Services, 2012–2019 ($Million)
Table 138 U.K.: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 139 U.K.: Market Size, By End User, 2012–2019 ($Million)
Table 140 Italy: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 141 Italy: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 142 Italy: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 143 Italy: Market Size, By Products & Services, 2012–2019 ($Million)
Table 144 Italy: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 145 Italy: Market Size, By End User, 2012–2019 ($Million)
Table 146 Spain: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 147 Spain: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 148 Spain: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 149 Spain: Market Size, By Products & Services, 2012–2019 ($Million)
Table 150 Spain: Blood Screening Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 151 Spain: Blood Screening Market Size, By End User, 2012–2019 ($Million)
Table 152 ROE: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 153 ROE: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 154 ROE: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 155 ROE: Market Size, By Products & Services, 2012–2019 ($Million)
Table 156 ROE: Blood Screening Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 157 ROE: Blood Screening Market Size, By End User, 2012–2019 ($Million)
Table 158 Asia: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 159 Asia: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 160 Asia: Blood Screening Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 161 Asia: Market Size, By Products & Services, 2012–2019 ($Million)
Table 162 Asia: Blood Screening Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 163 Asia: Market Size, By End User, 2012–2019 ($Million)
Table 164 Japan: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 165 Japan: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 166 Japan: Blood Screening Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 167 Japan: Market Size, By Products & Services, 2012–2019 ($Million)
Table 168 Japan: Blood Screening Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 169 Japan: Market Size, By End User, 2012–2019 ($Million)
Table 170 China: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 171 China: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 172 China: Blood Screening Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 173 China: Market Size, By Products & Services, 2012–2019 ($Million)
Table 174 China: Blood Screening Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 175 China: Market Size, By End User, 2012–2019 ($Million)
Table 176 India: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 177 India: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 178 India: Blood Screening Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 179 India: Market Size, By Products & Services, 2012–2019 ($Million)
Table 180 India: Blood Screening Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 181 India: Market Size, By End User, 2012–2019 ($Million)
Table 182 ROA: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 183 ROA: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 184 ROA: Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 185 ROA: Market Size, By Products & Services, 2012–2019 ($Million)
Table 186 ROA: Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 187 ROA: Market Size, By End User, 2012–2019 ($Million)
Table 188 ROW: Blood Screening Market Size, By Technology, 2012–2019 ($Million)
Table 189 ROW: Market Size for NAT, By Type, 2012–2019 ($Million)
Table 190 ROW: Blood Screening Market Size for ELISA, By Type, 2012–2019 ($Million)
Table 191 ROW: Market Size, By Products & Services, 2012–2019 ($Million)
Table 192 ROW:  Market Size for Reagents, By Type, 2012–2019 ($Million)
Table 193 ROW: Market Size, By End User, 2012–2019 ($Million)
Table 194 New Product Launches
Table 195 Mergers and Acquisitions
Table 196 Regulatory Approvals
Table 197 Partnerships and Agreements
 
 
List of Figures (34 Figures)
 
Figure 1 Research Methodology
Figure 2 Top-Down Approach
Figure 3 Bottom-Up Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 1 Blood Screening Market Snapshot, By Technology (2014 vs. 2019)
Figure 2 Reagents Segment Dominates Blood Screening Market With the CAGR of 10.9% During Forecasted Period
Figure 3 4th Generation ELISA is Largest Segment in 2014 Blood Screening ELISA Market and Would Continue Its Growth Story Till 2019
Figure 4 Blood Banks Segment is Largest Contributor and Fastest Growing Segment in Blood Screening Market During Forecasted Period
Figure 5 Global Blood Screening Market, By Region: North America Holds Largest Share and Asia is Fastest Growing Region in 2014
Figure 6 NAT Segment to Offer Attractive Growth Opportunities
Figure 7 Blood Screening Reagents Segment to Grow at Highest Rate
Figure 8 NAT Reagents Contributes Highest Share in Blood Screening Reagents Market
Figure 9 4th Generation ELISA Segment Expected to Grow at Highest CAGR in Asia During Forecasted Period
Figure 10 Blood Banks Dominates in Blood Screening Market and Witness Highest CAGR During Forecasted Period
Figure 11 China to Witness Highest Growth in Forecast Period
Figure 12 Technological Innovation and Differentiated Products Are Increasing Competition Among Market Players
Figure 13 NAT Testing Will Continue to Dominate the Market During the Forecast Period
Figure 14 Real-Time PCR Expected to Grow at A Double-Digit CAGR From 2014 to 2019
Figure 15 Asian 4th Generation ELISA Market Expected to Double By 2019
Figure 16 Reagents Segment Will Continue to Dominate the Blood Screening Market During Forecast Period
Figure 17 Asia is the Fastest-Growing Region in the Blood Screening Reagent Market
Figure 18 China to Witness the Highest Growth in the Blood Screening NAT Reagents Market in Asia
Figure 19 Blood Screening Market Segmentation, By End User
Figure 20 Blood Banks Segment Will Continue to Dominate the Blood Screening Market During the Forecast Period
Figure 21 Geographic Snapshot (2014): Emerging Markets Offer Significant Growth Opportunities in the Blood Screening Market
Figure 22 North America: Market Growth Will Be Driven By Innovative Blood Screening Instruments and Reagents
Figure 23 China Offers Immense Growth Opportunities for the Blood Screening Market
Figure 24 Battle for Market Share: New Product Launches Was the Key Strategy
Figure 25 Product Benchmarking for Top 5 Players
Figure 26 Grifols: Company Snapshot
Figure 27 Roche Diagnostics: Company Snapshot
Figure 28 Abbott Laboratories: Company Snapshot
Figure 29 Biomιrieux: Company Snapshot
Figure 30 Bio-Rad Laboratories, Inc.: Company Snapshot
Figure 31 Siemens AG : Company Snapshot
Figure 32 Thermo Fisher Scientific, Inc.: Company Snapshot
Figure 33 Danaher Corporation: Company Snapshot
Figure 34 Becton, Dickinson and Company: Company Snapshot

The blood screening market is a growing field that has witnessed a number of technological advancements since its inception, such as a shift from first-generation ELISA to advanced NAT technologies. This market is driven by several factors including increasing number of blood donations and blood donors, rising awareness regarding the safety of donated blood, increasing patient affordability, increasing adoption of NAT, and rising demand of donated blood. However, factors such as high capital expenditure and operating cost of NAT and stringent regulatory approval processes are likely to hinder the growth of this market. The blood screening market in Asia is likely to provide an array of opportunities owing to the growing demand for donated blood, increasing disposable income (leading to adoption of NAT ), and increased focus of key players in the Asian region.

The blood screening market is expected to reach $2.55 billion by 2019 from $1.5 billion in 2014, growing at a CAGR of 10.4% from 2014 to 2019. The global market is segmented on the basis of products and services, technologies, end users, and regions.

On the basis of products and services, the global market is segmented into instruments (hardware), reagents, and software and services. The blood screening instruments market is further segmented into rental purchase and outright purchase; while the blood screening reagents market segment is classified into ELISA reagents, NAT reagents, and other reagents.

On the basis of technologies, the global global market is segmented into nucleic acid tests (NAT), enzyme-linked immunosorbent assays (ELISA), enzyme immunoassays (EIAs) and chemiluminescent immunoassays (CLIAs), next-generation sequencing (NGS), and Western blot assays. The blood screening NAT market is further segmented into transcription mediated amplification (TMA) and real-time PCR. The blood screening market for ELISA testing is further categorized into card methodology, first-generation, second-generation, third-generation, and fourth-generation ELISA.

Based on end users, the blood screening market is segmented into blood banks and hospitals.

Blood Screening Market, by Region, 2014

Blood Screening Market

Source: Annual Reports, SEC Filings, Press Releases, Investor Presentations, World Health Organization (WHO), United States Food and Drug Administration (USFDA), Centers for Disease Control and Prevention (CDC), Red Cross Society, AVERT, Expert Interviews, and MarketsandMarkets Analysis

The global blood screening market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America will continue to lead the global blood screening market in the forecast period. Over the next five years, the growth of this market in the Asian region is likely to be centered on China, India, and South Korea.

The key players in the market include Grifols (Spain), Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Bio-Rad Laboratories (U.S.), Siemens Healthcare (Germany), bioMιrieux (France), Ortho Clinical Diagnostics, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Beckman Coulter (U.S.), and Becton, Dickinson and Company (U.S.).

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth In-Vitro Diagnostics Markets on KnowledgeStore
Request Demo